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ABSTRACT 
 
Background: Depressive disorders, including mild to moderate depression, are common illnesses 
that affect an estimated 1 in 5 individuals and account for substantial societal and individual costs.  
Cost is one barrier to an individual seeking treatment for depression with standard antidepressants.  
A more affordable antidepressant could lessen this barrier to the treatment of mild to moderate 
depression.  Inexpensive extracts of the flowering plant Hypericum perforatum (St. John’s wort or 
SJW) have long been used as an alternative treatment for depression.  While the popularity of SJW 
has been growing in the US, there is still doubt as to its effectiveness.  The purpose of this review is 
to examine the effectiveness of SJW alone compared to placebo or to other antidepressants in the 
treatment of mild to moderate depression. 
 
Methods: I conducted a literature search for randomized clinical trials of human subjects 
published in English between 1998 and 2004 using MEDLINE, BIOSIS v3.0, Alt Health Watch, 
AMED, and CINAHL.  I used the key words “antidepress*,” “depress*,” “hyperic*,” “john’s wort,” 
“johns wort,” “johnswort,” “blind*,” “random*,” “clinical trial,” “rct,” and “placebo.”  To be 
included in the analysis, a study must: 1) randomize subjects, 2) compare SJW alone to either 
placebo or other antidepressant, 3) enroll subjects >= 18 years old, 4) use the Hamilton Depression 
Rating Scale (HAM-D) to measure outcome, 5) study patients with mild to moderate depression, and 
6) define “response” as one whose HAM-D score decreases by >50% from baseline or is <= 10 at 
the end of the trial.  I excluded studies with subjects under 18 years old and those that used a 
different definition for “response,” did not compare SJW to placebo or other antidepressant, or 
included subjects with depressive disorders other than mild to moderate depression.  Once I 
extracted relevant data from each trial, I performed a meta-analysis using the MIX 1.7 program. 
 
Results:  Of 68 articles identified through the literature search, 12 studies met a priori criteria 
for inclusion in the analysis.  Five studies compared SJW to placebo, 5 studies compared SJW to 
other antidepressants, and two studies compared SJW to both placebo and another antidepressant.  
Five of 7 studies reported SJW was significantly more effective than placebo in treating mild to 
moderate depression.  These 7 studies included 1510 subjects, lasted 6 to 8 weeks, and used doses of 
SJW ranging from 500 to 1500-mg per day.  Tests for heterogeneity among studies were not 
significant.  The test for publication bias was also not significant.  Meta-analysis produced pooled 
outcomes measure for three comparisons.  Significant difference in response was found between 
SJW and placebo, but not between SJW and other antidepressants, or SJW and SSRI. 
 
Discussion: Results of this analysis of 12 studies suggests that treatment with SJW is 
significantly more effective than placebo and equivalent to other antidepressants, and SSRI’s, in 
treatment of adults with mild to moderate depression.  The strength of these conclusions is lessened 
by the small sample of included studies.  As the popularity of SJW continues to grow, further studies 
will be necessary to determine a standard dosing regimen and to study adverse effects and to better 
study effectiveness.  There is not currently enough of a database of adequate trials to draw final 
conclusions on SJW effectiveness versus placebo or other antidepressants.  In spite of these 
limitations, SJW potentially offers a less expensive alternative to standard antidepressant 
medications. 
 2 
INTRODUCTION 
 
Depression 
 
 Unipolar depressive disorders include major depression, which can be classified as mild 
to severe, and dysthymic disorder.
1
  In any given year, depressive disorders affect about 9.5% of 
the general population 18 and older and it is estimated that one-third of individuals will suffer at 
least one depressive episode during their lifetime.  As of 1990, unipolar major depression 
accounted for 10.7% of years lived with disability worldwide, 6.1% of all disability adjusted life 
years (DALY) in developed nations, and 10.3% of DALY in persons aged 15 to 44 worldwide.  
By 2020 unipolar depression is projected to be second only to ischemic heart disease as a cause 
of disability worldwide.  Dysthymic disorder, a chronic and mild form of depression, is more 
prevalent than unipolar depression with a lifetime prevalence of 5.4% among US adults 18 and 
older.  An estimated 10.9 million persons are affected by dysthymia each year, with an estimated 
9.9 million affected by unipolar depression.  About 2 in 5 of those diagnosed with dysthymia will 
be meet criteria for major unipolar depression later in life.
2
  Any estimate of prevalence of 
depressive disorders or of their economic impact is likely an underestimate since depression 
often goes undiagnosed and unreported.
3 
  Even those who go undiagnosed, however, will likely 
seek treatment for their symptoms of depression. 
 The majority of those with a diagnosable depressive disorder have dysthymic disorder, a 
form of depression that is mild and chronic.  These patients are more likely to use 
complementary and alternative medicines (CAM) in an effort to manage their condition without 
doctor’s visits or prescription medications.  Although CAM therapies already enjoy widespread 
use, it is important to gather evidence to support, or refute, their effectiveness.  It is at least as 
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important to collect and analyze data on adverse effects from CAM therapies as it is to establish 
whether or not they are effective.   
 
Complementary Treatments for Depression 
 The Cochrane Collaboration defines complementary and alternative medicine (CAM) as 
“diagnosis, treatment, and/or prevention which complements mainstream medicine by 
contributing to a common whole, by satisfying a demand not met by orthodoxy, or by 
diversifying the conceptual frameworks of medicine.”4  The popularity of CAM therapies has 
grown recently, with as many as 40% of adults using at least one CAM therapy for at least one 
year as of 1998.
5
  The popularity of CAM therapies can be attributed to the patient’s desire to 
find treatments with fewer adverse effects as well as to the perception that alternative therapies 
are less authoritarian and more empowering, allowing the patient to take more control over their 
treatment.
6  
Depression ranks as one of the more popular conditions for which patients choose a CAM 
therapy and a variety of therapies have been cited as useful in treatment of depression.  These 
treatments include therapies focusing on movement, such as applied kinesiology and exercise, 
and those that employ touch, like acupuncture and massage.  Hypnotherapy uses hypnosis to help 
relieve depressive symptoms, while Naturopathy focuses on enhancing the body’s own ability to 
heal itself.  Other philosophies hold that disease states can be manipulated by simple elements 
like oxygen or color or that illness can be treated through principles of faith.  Remedies based on 
herbs or plants include aromatherapy, medical herbalism, and phytomedicine.
6
  Relaxation, 
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exercise, and herbal treatments, such as St. John’s wort, rank as the most often utilized CAM 
therapies in the treatment of depression.
4
 
 
History of St. John’s Wort 
 Hypericum perforatum, a perennial herb found growing in Europe, Western Asia, North 
Africa, and North America, is a shrub whose yellow blossoms produce a sap when crushed.  This 
sap is also known as Andro Haimon, or Mar’s blood, due to its blood-like appearance and 
consistency.
7
  Hypericum perforatum gained part of its popular name from its tendency to flower 
in late June, around the birthday of St. John the Baptist, as well as from the tradition of gathering 
the herb’s yellow flowers as part of the feast to celebrate St. John.8, 9  The moniker of St. John 
was combined with “wort,” the Old English word meaning plant, to give the full popular name of 
St. John’s wort.8, 10 
History is ripe with examples of Hypericum’s use in treating conditions such as 
depression, anxiety, and insomnia.
8, 11, 12
  The medical school of Salerno lists “herba demonis 
fuga” (herb that chases away the devil) in its 13th century list of medicinal plants.  In 1525, 
Paracelsus reports using Hypericum for the treatment of depression, melancholy, and over-
excitability (most likely anxiety).  Early 17
th
 century Franciscan monks used “fuga demonum” 
(the devil’s scourge) to ward off evil spirits and demonic possession.8, 10  The above examples 
demonstrate a long-standing belief that Hypericum has properties effective in treating mental 
illness. 
St. John’s wort has enjoyed its most widespread use as an antidepressant medication in 
Germany gaining both the official approval of the German government and the largest share of 
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the antidepressant market.
12
  In Germany, sales of St. John’s wort exceed sales of all other 
antidepressants combined with 20 times more prescriptions written for St. John’s wort than for 
Prozac.
13,14
  In spite of its popularity and well-established use in parts of Europe, questions 
remain concerning both the effectiveness and safety of the herb.   
 
Previous Studies 
Past clinical trials have attempted to demonstrate the herb’s effectiveness in treating 
depression.  Serious methodological flaws weakened conclusions of earlier trials primarily 
conducted in Germany.  Failure to use intention-to-treat analysis or to use statistical tests of 
significance to compare responder rates of the treatment group to rates of the placebo group are 
two of the more common flaws of these early studies.
8
  Many studies were too short to allow for 
meaningful comparison.
12
  Studies intending to compare St. John’s wort to other antidepressants 
have often failed to use a high-enough dose of the antidepressant to allow for meaningful 
comparisons with the herbal treatment.
12
  Failure to use DSM-IV criteria to properly identify 
mildly to moderately depressed subjects may constitute the most serious methodological flaw of 
earlier studies.  Many of these studies used subjects whose diagnoses were more consistent with 
acute stress disorder or adjustment disorder with depressed mood.  Symptoms caused by these 
conditions were more likely to fluctuate or spontaneously resolve over the course of a trial when 
compared to symptoms caused by a primary depressive disorder.
12
  Results of trials conducted 
with such serious methodological flaws are of little value in evaluating St. John’s wort’s 
effectiveness or safety. 
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 Popularity of St. John’s wort has been growing in the U.S. primarily through promotion 
by popular media outlets.  In addition to the media’s portrayal of St. John’s wort as safe and 
effective, characteristics of the U.S. population have also helped drive the herb’s popularity.  
Many believe that herbal products are more natural and therefore safer than other 
pharmaceuticals.  Some find the fact that no prescription is required for St. John’s wort an 
attractive quality.  By avoiding an interaction with a mental health professional and the 
pharmacist, these individuals can avoid any personal acknowledgement of mental illness, thus 
avoiding the societal stigma of mental illness.
12
  Regardless of the reason, use of St. John’s wort 
by Americans has been on the rise, demonstrated by recent increases in sales of the supplement 
as well as by the availability of St. John’s wort in retail outlets and through internet vendors.15, 16 
 
Placebo Controversy 
Over time, studies have shown that there is a substantial and widely variable placebo 
effect operating among patients being treated for depression.  Recent research has also indicated 
that this placebo effect may be increasing in magnitude.
17
  With such a strong placebo effect 
confounding studies of novel antidepressants, it becomes necessary to compare any new 
treatment to both placebo and an active comparator, such as an SSRI or TCA.  For example, if a 
Hypericum perforatum extract is compared only to an SSRI, then the study may prematurely 
conclude that the effects of Hypericum are equivalent to the SSRI.  On the other hand, if 
Hypericum is compared only to placebo, then the study is more likely to conclude that 
Hypericum is not more effective than placebo.
18
 
 7 
The existence of such a powerful placebo effect demands a certain progression of studies 
before one can draw conclusions concerning the effectiveness of a novel therapy.  Written in 
2002, the National Manic-Depressive Association Consensus Statement on the use of placebo in 
clinical trials of mood disorders states that a new drug must first be found to be more effective 
than placebo before studies between the new drug and standard treatments can conclude the 
novel treatment is effective.
19
  In order to accurately assess Hypericum’s effectiveness, one must 
first determine whether or not it is significantly more effective than placebo.  Should these 
studies show Hypericum is more effective than placebo, focus can shift to whether or not 
Hypericum’s effects are equivalent to those of standard antidepressants.  In addition, it is 
important that this second group of studies also include a placebo group to properly account for 
placebo effect.
19
 
Two studies to date have compared a Hypericum perforatum extract to both placebo and 
an active comparator.  Philipps and associates compared the effects of Hypericum to both 
placebo and Imipramine in the treatment of moderately depressed subjects.
20
  This group used 
the HAM-D to measure change in symptoms over an 8-week period in patients randomly 
assigned to treatment with a maximum dose of 100-mg Imipramine, Hypericum extract 
containing 0.2 to 0.3% hypericin, or placebo.  Hypericum was shown to be more effective than 
placebo and at least as effective as the dose of Imipramine used in the study.  Given its positive 
effects and favorable side effect profile, this group concluded that Hypericum was effective, safe, 
and improved symptoms of moderately depressed subjects.
20
  The Hypericum Depression Trial 
Study Group (HDTSG) compared the effects of an extract of Hypericum containing 0.12 to 
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0.28% hypericin to Sertraline and placebo.  This group did not find any differences between 
Hypericum and placebo or between Hypericum and Sertraline.
21
 
 
Public Health Issue
 
 While the FDA regulates labeling and restricts the types of claims that can be made about 
dietary supplements, manufacturers are currently not required to prove effectiveness or safety of 
products either before or after releasing them to market.
22-27
  Since supplements do not undergo 
pre-market testing or post-market surveillance, it important for independent groups to more 
closely study both St. John’s wort’s effectiveness and safety profile using methodologically 
sound techniques.  It is the purpose of this paper to systematically review studies on the 
effectiveness of St. John’s wort in treating mild to moderate depression.  A meta-analysis of 
relevant studies will also be conducted, if appropriate. 
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 METHODS 
Search Methods 
 I identified relevant articles using a systematic search strategy limited to randomized 
control trials published in English language journals.  Articles published from January 1998 to 
October 2004 were retrieved from online PubMed, BIOSIS v3.0, Alt Health Watch, AMD 
(Alternative Medicine), and CINAHL databases.  I chose this date range based on trends noted in 
the published literature.  Studies of SJW published prior to 1998 have been criticized for their 
methodological weakness.  These methodological weaknesses include 1) used of inexperienced 
investigators, 2) failure to use a standardized instrument to measure depressive symptoms, 3) use 
of non-standard diagnostic criteria leading to heterogeneous study groups, and 4) short study 
duration.
28
  In addition, studies prior to 1998 were conducted primarily in Europe and published 
in lesser-known journals.  Studies published since 1998 have attempted to address the 
aforementioned methodological weaknesses and have more often been published in more 
respected journals. 
 Key words used in the initial search included “antidepress*,” “depress*,” “hyperic*,” 
“john’s wort,” “johns wort,” “johnswort,” “blind*,” “random*,” “clinical trial,” “rct,” and 
“placebo.”  Medical subject headings (MeSH) terms used in the search included “antidepressive 
agents,” “depressive disorders,” “depression,” and “Hypericum.”  I have summarized search 
terms used in this search below in Table 1.  I consulted a research librarian both during and 
following the search to confirm that I had conducted a complete and systematic search.   
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Table 1. List of terms, key words, and limits used in the systematic search of the literature 
for studies comparing SJW to either placebo or other antidepressants for the treatment of adults 
with mild to moderate depression. 
 
[MeSH Terms]  [Key Words]   [Search Limits] 
Antidepressive agents  antidepress* blind*  English language 
Depressive disorder  depress* random* 1998 to October 2004 
Depression   hyperic* placebo* 
Hypericum   john’s wort clinical trial 
    johns wort rct 
    johnswort 
 
 
A priori criteria for identifying studies 
 I evaluated all potentially relevant articles identified through the literature search using a 
priori inclusion criteria.  Only articles that met all criteria would be included in the analysis.  To 
be included, studies must 1) be randomized, 2) compare SJW alone to either placebo, another 
antidepressant, or both, 3) enroll subjects older than 18 years of age, 4) utilize the Hamilton 
Depression rating scale (HAM-D) to measure clinical outcome, 5) study patients with mild to 
moderate depression, and 6) define “response” as a greater than or equal to 50% decline from 
baseline HAM-D score or a HAM-D score of less than 10 by the end of the study.  Inclusion 
criteria are listed below in Table 2. 
 
Table 2. A priori criteria used to identify articles for inclusion in comparison of 
effectiveness of SJW in treating mild to moderate depression versus placebo or other 
antidepressant. 
 
1) Randomized allocation of subjects, 
2) Compare SJW alone to placebo, other antidepressant, or both, 
3) Enroll subjects greater than 18 years old, 
4) Use HAM-D to measure clinical outcome, 
5) Study patients with mild to moderate depression, 
6) Define “response” as  50% decline from baseline HAM-D or final HAM-D < 10. 
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 According to the DSM-IV, mild to moderate depression is defined by number of criteria 
symptoms present, severity of symptoms, and degree of dysfunction resulting from the condition.  
To be diagnosed with depression, a patient must exhibit a depressed mood and/or marked 
decrease in enjoyment from or interest in activities they normally enjoy.  Additionally, the 
patient must exhibit three or more of the following: 1) weight loss or gain, 2) sleeping more or 
less than usual, 3) psychomotor retardation, 4) fatigue, 5) feelings of guilt or worthlessness, 6) 
decreased ability to concentrate, and 7) recurrent thoughts of death or suicide.  Symptoms must 
be present for at least two weeks for the diagnosis to be made.
29
 
Mild depression is diagnosed when five or six depressive symptoms (depressed mood 
and/or anhedonia with 3-4 other symptoms) of mild intensity are present for a two-week period.  
While mildly depressed subjects require substantial effort to navigate normal activities, these 
persons suffer only mild functional impairment.  Moderate depression is defined by the presence 
of a few depressive symptoms in excess of the minimum needed for diagnosis.  Moderate 
depression may also be diagnosed with minimum symptoms, but only if those symptoms are of 
moderate intensity and lead to greater functional impairment than seen in mild depression.
29
  
Mild to moderate depression is further described as uncomplicated by such co-morbidities as 
substance abuse, eating disorders, cognitive dysfunction, panic disorder, bipolar disorder, 
personality disorder, psychosis, or post-traumatic stress disorder.
28
  Therefore, I excluded any 
studies that included patients with these complications from this analysis.  I chose the definition 
for “response” to treatment based on its standard use in clinical trials of the effectiveness of 
antidepressants in treating depression.
30
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 For use in research, DSM-IV definitions of mild to moderate depression are translated 
into a specific score on an instrument used to measure depressive symptoms.  The 17-item 
HAM-D (HAM-D 17), the instrument used most often to measure primary end-points in 
antidepressant trials, has a maximum value of 52.  “Severe” depression is defined by a score or 
equal to or greater than 28.  A score from 16 to 27 defines “Moderate” depression and a score 
from 8 to 15 represents “mild” depression.  “Remission” is defined as a score equal to or lesser 
than 7.
30
 
 
Article Selection 
 I reviewed randomized trails comparing the effectiveness of SJW to that of placebo or 
other antidepressants in treating adults (18 years or older) with mild to moderate depression.  
Only studies that used HAM-D scores to measure the primary outcome, “response” to treatment, 
were included.  Following the literature search described above, I systematically reviewed titles 
and abstracts of articles and excluded articles that did not meet a priori criteria for inclusion.  
Had time and resources allowed, a second reader would have independently reviewed the articles 
identified through the literature search.  Any disagreements over an articles inclusion would then 
have been adjudicated by evaluation of the complete article by both reviewers.  After more 
extensive review, the reviewers would then come to a mutual decision on the articles inclusion or 
exclusion.  Please see Figure 1 for a summary of article selection. 
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Articles identified through initial search
for randomized, double-blinded,
control trials comparing SJW to
either placebo or to another Title Review
antidepressant (N = 68). 30 articles did not meet inclusion
criteria.
*Did not study SJW in treatment of
depression.
n = 38 *Studied several herbal supplements.
*Discussed ethical issues.
Abstract Review
21 articles did not meet criteria for
inclusion.
*Review articles.
n = 17 *Re-evaluated previously published
data.
Two (2) continuation studies were
excluded.
n = 15
One (1) study excluded for lack of
comparator group
One (1) excluded for inclusion of
n = 12 severely depressed subjects.
One (1) excluded for lack of
"response" definition.
SJW vs. Placebo SJW vs. Placebo or Other SJW versus Other
Antidepressant
Five (5) studies Two (2) studies included. Five (5) studies
included. included.
Figure 1. Flow diagram of literature search and application of a priori  inclusion 
criteria to identify studies for systematic review.
 
 
Internal Validity 
 Any study that failed to meet all of the stated inclusion criteria, or that reported data from 
an earlier study, was excluded from further analysis.  I then reviewed studies that met inclusion 
criteria and judged the internal validity of the methods used by the following criteria: 1) was 
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subject randomization successful, 2) did randomized subjects meet the definition of “mild to 
moderate” depression according to baseline HAM-D score, 3) was intention-to-treat (ITT) 
method used in analysis, 4) did randomized subjects represent a typical primary care population, 
5) were study subjects blinded, and 6) did loss to follow-up or crossovers significantly affect 
groups measured at the study’s endpoint.  Criteria used to assess internal validity of included 
studies are listed below in Table 3.   
 
Table 3. Criteria used to assess internal validity of articles included in comparison of 
effectiveness of SJW to that of placebo or other antidepressants in treating adults with mild to 
moderate depression. 
 
1) Were study subjects effectively randomized? 
2) Do randomized subjects meet definition of “mild to moderate” depression according to 
baseline HAM-D score? 
3) Was intention-to-treat (ITT) analysis used? 
4) Do randomized subjects represent a typical primary care population or are they more 
representative of a selective group? 
5) Were subjects blinded to their group allocation? 
6) Did loss to follow-up or crossover significantly affect groups when measured at the 
study’s endpoint? 
 
 
 Once assessed for internal validity, I assigned each study a grade of “good,” “fair,” or 
“poor.”  If a study met all validity criteria, then it was deemed “good.”  Studies meeting most 
criteria, and free of any major flaws, were graded as “fair.”  Major flaws included 1) ineffective 
randomization, 2) inclusion of a highly specific group of subjects, 3) failure to use ITT analysis, 
4) failure to blind subjects to group, and 5) patient attrition so great that it affects the final 
analysis.  Studies found to have a major flaw were graded “poor” regardless of their adherence to 
other criteria.  Had time and resources not limited this study, a second reader would have 
independently evaluated internal validity of included studies according to the criteria listed 
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above.  Once the second reader had graded each article, the two readers would have met to 
discuss any differences in grading.  Once identified, grading differences would then have been 
resolved through consensus. 
 
Analysis 
 Prior to statistical analysis, I performed a narrative analysis of the included papers.  I 
started by critically reading each paper with a focus on the methods section.  Close reading of 
each included study allowed me to perform a detailed comparison of studies that compared SJW 
to placebo and, then, SJW to other antidepressants.  Data used for comparison can be seen in 
appendices 1 and 2.  Had time and resources allowed, a second reader would have independently 
reviewed each paper and any discrepancies addressed. 
 In addition to systematically reviewing each study, I analyzed data from included studies 
to generate pooled outcome measures describing the effectiveness of SJW versus that of placebo 
and other antidepressants.  I extracted experimental and reference data from each included study 
and placed this data into one of four categories.  For studies comparing SJW to placebo, these 
categories included SJW responders, SJW non-responders, Placebo responders, and Placebo non-
responders.  For studies comparing SJW to other antidepressants, these categories included SJW 
responders, SJW non-responders, Other antidepressant responders, and Other antidepressant non-
responders.  I also made a third comparison that included SJW responders, SJW non-responders, 
SSRI responders, and SSRI non-responders.  I compared SJW to Placebo to determine if SJW 
had any positive effect in the treatment of depression while accounting for the placebo effect.  I 
compared SJW to Other antidepressants and SSRI to determine if treatment of depression with 
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SJW was equivalent to that of the other antidepressants.  Had time and resources allowed, a 
second reader would have independently reviewed abstracted data and any discrepancies would 
have been addressed with the first reader. 
 I used an Excel-based meta-analysis program, MIX 1.7, to perform all calculations and 
defined statistical significance using an alpha level of 0.05.
31, 32
  With the appropriate data 
extracted from included studies, I first evaluated included studies for statistically significant 
heterogeneity using the Cochran homogeneity statistic.  If there is no significant heterogeneity 
found, then it is appropriate to perform a meta-analysis.  Analysis of the Cochran result also 
allowed me to identify any important differences between studies so that these may be 
investigated further.  To facilitate such analysis, the MIX 1.7 program produces a funnel plot 
comparing study effects versus different aspects of the included studies (sample size, p-value, or 
standard error).  If appropriate, pooled outcome measures [risk ratios with 95% confidence 
intervals (CI)] will be reported for each comparison and presented in the form of a forest plot.  
The Mantel-Haenszel method will be used for these calculations and use of the fixed or random 
effects model will be based on whether or not there is statistically significant heterogeneity 
among included studies.  I will then analyze forest plots for each comparison to draw conclusions 
on the effectiveness of SJW compared to placebo and other antidepressants in treating mild to 
moderate depression. 
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RESULTS 
 Initial literature searches identified 68 citations.  A review of titles of these 68 articles 
revealed that 30 did not meet inclusion criteria.  Excluded articles were those that did not study 
the effects of SJW on mild to moderate depression, did not use human subjects, reviewed several 
herbal supplements used in treating depression (including SJW), or discussed ethical issues 
surrounding the use of placebo in clinical trials of antidepressants.  Closer examination of the 
abstracts of the remaining 38 articles identified 17 articles that warranted closer consideration for 
inclusion.  The 21 articles excluded during this examination consisted of review articles and 
papers that re-evaluated data published in earlier studies.  Of the 17 articles identified for closer 
evaluation, two were excluded because they were continuation studies and not studies of 
treatment for acute disease.  Another single article was excluded because, even though it studied 
three different concentrations of SJW, it had neither a placebo group nor an antidepressant group 
for comparison.  Two other studies were excluded, one because it did not define “response” and 
the other because it included severely depressed subjects.  The 12 remaining studies were 
included in the final analysis (please refer to Figure 1). 
 Of the 12 articles in the final analysis, 5 compared SJW to another antidepressant without 
using a placebo group.  One study used Imipramine as the active comparator, one used 
Paroxetine, two used Sertraline, and four used Fluoxetine.  Two studies compared SJW to both 
placebo and an active comparator.  One such study compared SJW to placebo and Imipramine 
while the other compared SJW to placebo and Sertraline.  Five studies compared SJW alone to 
placebo, without using an active comparator.  For this analysis, data from the studies that 
compared SJW to both placebo and an active comparator was used in both comparisons, SJW 
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versus placebo and SJW versus other antidepressant.  Data from seven studies was included in 
the comparison of SJW versus placebo and data from 7 studies was used in comparing SJW to 
other antidepressants. 
 
SJW versus Placebo 
 Seven studies were analyzed in making the comparison between SJW and placebo.
9, 33, 20, 
34, 28 ,21 ,35
  The studies by Shelton, et al 
28
 and the HDTSG 
21
 were conducted in the US while the 
others were conducted in Germany and France.  Five of the 7 studies defined mild to moderate 
depression at baseline according to DSM-IV criteria.
21, 28, 33, 34, 35
  Groups led by Schrader 
9
 and 
Philipp 
20
 used ICD-10 codes to define baseline depression.  Schrader’s group also used the 21-
item HAM-D to measure outcome while the other studies used the 17-item HAM-D.  Included 
studies randomized a total of 1510 subjects, lasted from 6 to 8 weeks, and tested 6 different 
preparations of SJW.  Doses of SJW used in these trials varied from 500-mg to 1500-mg per day 
divided into one to three daily doses.  Two of these studies also included another antidepressant 
arm.
20, 21
  Philipp’s group compared SJW to placebo and Imipramine and the HDTSG compared 
SJW to placebo and Sertraline.  One study, led by Laakmann, included two active arms, each 
using a different preparation of SJW extract.
33
  Data from this study was divided so that each 
extract could be compared to placebo individually. Details of the studies included for the 
comparison of SJW to placebo can be found in Table 4 and Appendix 1. 
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Table 4. Randomized, double blind trials comparing SJW to placebo, other antidepressant, or both.  
           
   Baseline HAM-D    Hypericum extract Other 
Study N 
DSM 
IV SJW Placebo Other End Preparation 
Dose 
(mg) Drug 
Dose 
(mg) 
Schrader 
(1998) 162 No 20.13 18.76   6 w Ze 117 500     
Laakmann 
(1998) 98 Yes 20.3 21.1  7 w WS 5573 900   
Laakmann 
(1998) 98 Yes 20.9 21.1  7 w WS 5572 900   
Philipp 
(1999) 263 No 22.7 22.7 22.2 8 w STEI 300 1050 Imipramine 100 
Kalb 
(2001) 72 Yes 20.1 19.7  6 w WS 5572 900   
Shelton 
(2001) 200 Yes 22 23  8 w LI 160 
900- 
1200  
HDTSG 
(2002) 340 Yes 23.1 22.7 22.5 8 w LI 160 
900-
1500 Sertraline 
50-
100 
Lecrubier 
(2002) 375 Yes 21.9 21.9  6 w WS 5570 900   
Harrer 
(1999) 149 No 16.6  17.18 6 w LoHyp-57 800 Fluoxetine 20 
Brenner 
(2000) 30 Yes 21.3  21.7 7 w LI 160 900 Sertraline 75 
Schrader 
(2000) 240 No 19.65  19.5 6 w Ze 117 500 Fluoxetine 20 
Woelk 
(2000) 324 No 22.4  22.1 6 w Ze 117 500 Imipramine 150 
Behnke 
(2002) 70 No 20   20.7 6 w Calmigen 300 Fluoxetine 40 
Notes:           
a. All studies that did not use DSM-IV criteria to define depression used appropriate ICD-10 codes. 
b. Both studies invovling Schrader used the 21-item HAM-D. All others used the 17-item HAM-D.  
c. Laakmann, et al (1998) included two active arms, each testing a different Hypericum extract.  
These arms are presented separately.        
 
SJW versus Other Antidepressant 
 Seven studies were analyzed in making the comparison between SJW and other 
antidepressants.
20, 21, 36, 37, 38, 39, 40
  Studies by the HDTSG 
21
 and Brenner, et al 
37
 were conducted 
in the US while the others were conducted in Germany.  Five of the 7 studies defined mild to 
moderate depression at baseline according to ICD-10 codes while only Brenner, et al 
37
 and 
 20 
HDTSG 
21
 used DSM-IV criteria.  The study by Schrader 
38
 used the 21-item HAM-D to 
measure outcome while the other studies used the 17-item HAM-D.  Included studies 
randomized a total of 1416 subjects, lasted from 6 to 8 weeks, and tested 5 different preparations 
of SJW.  Doses of SJW used in these trials varied from 300-mg to 1500-mg per day divided into 
one to three daily doses.  Groups led by Philipp and Woelk tested SJW versus the tricyclic 
antidepressant Imipramine.
20, 39
  Five studies compared SJW to a selective serotonin reuptake 
inhibitor (SSRI), with two studies using Sertraline 
21, 37
 and three studies using Fluoxetine.
36, 38, 40
  
Imipramine doses used ranged from 100-mg daily to 150-mg daily.  Sertraline doses used ranged 
from 50-mg to 100-mg per day and Fluoxetine doses used ranged from 20-mg per day to 40-mg 
per day.  Details of the studies included for the comparison of SJW to other antidepressants can 
be found in Table 4 and Appendix 2. 
 
SJW versus Placebo and Other Antidepressant 
 Two studies were identified that compared SJW to both placebo and another 
antidepressant.
20, 21
  The HDTSG conducted its work in the US while the group led by Philipps 
performed their study in Germany.  The HDTSG 
21
 used DSM-IV criteria to define mild to 
moderate depression at baseline while the Philipps group used ICD-10 codes.
20
  Both studies 
used the 17-item HAM-D to measure outcome.  These studies randomized a total of 603 subjects 
that were split into two comparisons (SJW versus placebo, SJW versus other antidepressant) and 
included in separate comparisons.  Both studies lasted 8 weeks, but tested different preparations 
of SJW against different antidepressants.  Doses of SJW used in these trials varied from 900-mg 
to 1500-mg per day divided into one to three daily doses.  Philipp and associates tested SJW 
 21 
versus placebo and versus 100-mg of Imipramine daily.
20
  The HDTSG studied SJW versus 
placebo and versus 50 to 100-mg of Sertraline daily.
21
  More detail on the studies included for 
the comparison of SJW to other antidepressants can be found in Appendices 1 and 2. 
 
Other Characteristics 
 Close evaluation of included studies revealed other differences between studies.  Five of 
the included studies used a placebo run-in period for all groups prior to initiation of placebo or 
intervention.
33, 34, 28, 21, 35
  In the studies that compared SJW to placebo, the placebo response rate 
ranged from 13.5% to as high as 63%.  Three studies did not standardize the dose of SJW used 
according to amount of active ingredient.
36-38
  The remainder of the included studies did take 
steps to standardize the dose of active ingredient used in the SJW arm.  There also exists some 
between groups differences in the level of depression [low moderate (HAM-D 16 to 20) versus 
high moderate (HAM-D 20 to 24)] measured at baseline.  Details of these other study 
characteristics can be seen in Table 5 below. 
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Table 5. Other characteristics of included studies.   
Study Placebo Placebo Standard Baseline HAM-D Baseline HAM-D 
 run-in? response SJW dose 
16-20  
(low moderate) 
20-24  
(high moderate) 
Schrader, et al (1998) No 13.50% Yes placebo Ze 117 
Laakmann, et al 
(1998)                     a Yes 32.70% Yes  placebo 
     WS 5573 
Laakmann, et al 
(1998)                     b Yes 32.70% Yes  placebo 
     WS 5572 
Philipp, et al (1999) No     c 63% Yes  placebo 
     STEI 300 
     Imipramine 
Kalb, et al (2001) Yes 42.90% Yes WS 5572 placebo 
Shelton, et al (2001) Yes 18.60% Yes  placebo 
     LI 160 
HDTSG (2002) Yes 43.10% Yes  placebo 
     LI 160 
     Imipramine 
Lecrubier, et al (2002) Yes 42.30% Yes  placebo 
     WS 5570 
Harrer, et al (1999) No None No Lo-Hyp-57  
    Fluoxetine  
Brenner, et al (2000) No     c None No  LI 160 
     Sertraline 
Schrader (2000) No     c None No Ze 117  
    Fluoxetine  
Woelk (2000) No None Yes  Ze 117 
     Imipramine 
Behnke, et al (2002) No None Yes  Calmigen 
          Fluoxetine 
Notes:      
a, b.  These are the two active arms of Laakmann, et al (1998).  Each arm tests a different 
Hypericum extract.      
c.      Philipp, et al (1999); Brenner, et al (2000); and Schrader (2000) used a "wash-out" period 
prior to initiating treatment or placebo.     
 
 
Internal Validity 
 Studies were assigned a grade of good, fair, or poor based on their adherence to a priori 
criteria for internal validity (see Table 3 above).  Of the studies that compared SJW to placebo, 
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four were judged to be good studies.  Laakmann, et al 
33
 satisfied all criteria.  Studies led by 
Shelton,
28
 HDTSG,
21
 and Lecrubier 
35
 included subjects that scored above 24 on the baseline 
HAM-D, and did not fit the definition of mild to moderate depression.  In their study, the 
HDTSG set out to address methodological flaws identified in past studies.
21
  This group took 
extra measures to assess their own methods including statistical analysis to measure the 
effectiveness of subject blinding.  Their analysis concluded that blinding was significantly less 
effective in the Sertraline group, likely secondary to medication side effects.  In addition, the 
HDTSG group had less than 80% follow-up, though statistical analysis revealed that dropout was 
evenly distributed across groups.  None of the other studies in this group employed methods to 
assess effectiveness of blinding or to evaluate loss of subjects to follow-up.  In spite of the 
aforementioned issues, the study by HDTSG was graded a good study. 
 Two studies in this group were deemed fair.  Philipp and associates earned a fair grade by 
including subjects that did not meet the definition of mild to moderate depression at baseline and 
by not reporting how they blinded subjects to study group.
20
  The study by Kalb, et al was judged 
as fair in spite of the fact that it met all criteria used to judge internal validity.  This study’s 
conclusions were weakened by a small sample size and short duration.
34
  One study in this group, 
by Schrader and associates, was considered to be a poor study.  This study suffered a fatal flaw 
when randomizing subjects to different study groups.  The HAM-D scores of the SJW were 
found to be significantly higher than those of the placebo group when measured at baseline.
9
 
 Among studies that measured the effectiveness of SJW versus another antidepressant, 
three were judged as good.  The study by HDTSG may have included subjects that did not meet 
the definition of mild to moderate depression and may not have adequately blinded subjects to 
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allocation, but the study was still strong.  The HDTSG made efforts to evaluate the methods used 
to blind subjects and further investigate loss to follow-up were representative of a 
methodologically rigorous study.
21
  The study by Woelk was good in spite of including subjects 
that did not meet the definition of mild to moderate depression and greater loss to follow-up in 
the Imipramine group.
39
  Sample size and evaluation of the remainder of study method were 
considered rigorous enough to earn a good grade.  Schrader met all criteria set forth to evaluate 
internal validity.
38 
 Three studies that compared SJW to another antidepressant were judged to be fair.  
Philipp and associates included subjects that did not meet the definition of mild to moderate 
depression and did not report the method used to blind subjects to study group.
20
  Brenner, et al 
did not use a standard pill size across study groups rendering blinding ineffective.  This study 
also suffered from greater than 20% loss of subjects at follow-up.
37
  Behnke, et al suffered from 
differential loss to follow-up, with the SJW group losing more than the Fluoxetine group, and 
failed to report the method used to blind subjects to group.
40
  Harrer, et al was found to be a poor 
study.  This study also failed to use a standard pill size across groups, thus negatively affecting 
blinding.  In addition, the Fluoxetine group lost more than twice as many subjects to follow-up 
and the population studied was not representative of a primary care population.
36
  Please see 
Table 6 below for a summary of Internal Validity assessment. 
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Table 6. Assessment of internal validity in included studies. 
  Mild-Mod  Prim. Subjects Sig. loss Study 
Study Random Depression ITT Care blinded to f/up Grade 
Schrader 
(1998) No    a Yes Yes Yes Yes No poor 
Laakmann 
(1998) Yes Yes Yes Yes Yes No good 
Philipp 
(1999) Yes No Yes Yes ? No fair 
Kalb 
(2001) Yes Yes Yes Yes Yes No fair 
Shelton 
(2001) Yes No    b Yes Yes Yes No good 
HDTSG 
(2002) Yes No    b Yes Yes No   d, j No   k good 
Lecrubier 
(2002) Yes No    b Yes Yes Yes No good 
Harrer 
(1999) Yes Yes Yes 
No    
c No    e Yes   f poor 
Brenner 
(2000) Yes Yes Yes Yes No    e Yes   g fair 
Schrader 
(2000) Yes Yes Yes Yes Yes    j No good 
Woelk 
(2000) Yes No     b Yes Yes Yes    j Yes   h good 
Behnke 
(2002) Yes Yes Yes Yes ? Yes   i fair 
Definitions:        
"Mild to  moderate" depression = baseline HAM-D 17-item score of 16 to 24. 
Effects of loss-to-follow up = Distribution of subjects lost from each group. 
Randomization = Assessed reported method and baseline group characteristics. 
Blinding of subjects = Assessed by evaluation of reported method.  
Notes:        
a. Schrader (1998) SJW group had baseline HAM-D scores higher than placebo 
b. Philipp (1999); Shelton (2001); HDTSG (2002); Lecrubier (2002); Woelk 
(2000) included subjects who scored above 24 on baseline HAM-D 
c. Harrer (1999) enrolled elderly subjects ages 60 to 80 years old 
d. HDTSG (2002) analyzed effectiveness of blinding, found blinding was less 
effective in Sertraline group 
e. Neither Harrer (1999) nor Brenner (2000) used standard pill size. 
f. Harrer (1999) fluoxetine lost 23.5% to follow-up, SJW lost 11.6% 
g. Brenner (2000) had less than 80% follow-up    
h. Woelk (2000) imipramine lost 17.9% to follow-up, SJW lost 9.6%.  
i. Behnke (2002) fluoxetine lost 8.6% to follow up, SJW lost 17.1%. 
j. HDTSG (2002); Schrader (2000); and Woelk (2000) used double-dummy 
method to ensure subjects were blinded to treatment.    
k. HDTSG (2002) had less than 80% follow-up, loss-to-follow up was even.  
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Comparisons 
SJW versus Placebo 
 Seven studies, with the study by the Laakmann group split into two samples, were 
included in the comparison of SJW versus placebo in the treatment of mild to moderate 
depression.
33
  The Cochran calculation revealed that there was not significant heterogeneity 
between included studies and that it would be appropriate to combine these studies into one 
meta-analysis.  The pooled risk ratio for this comparison, calculated using a random effects 
model, was 1.3633 [95% CI: 1.0846 to 1.7138] with a p-value of 0.0079.  These results 
demonstrate a statistically significant difference between the SJW and placebo groups, with an 
increased response rate in the SJW group.  Please see figure 2 for a forest plot of the results from 
this meta-analysis. 
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Figure 2. Forest plot produced through meta-analysis of included studies comparing SJW to 
placebo.  The pooled risk ratio for this comparison, calculated using a random effects model, was 
1.3633 [95% CI: 1.0846 to 1.7138] with a p-value of 0.0079.  This comparison indicates that 
there is a significant difference in response to treatment with SJW versus placebo in favor of 
response.  This demonstrates that SJW is more effective than placebo in treating mild to 
moderate depression. 
 
 
SJW versus Other Antidepressant 
 Seven studies were included in the comparison of SJW versus other antidepressant in the 
treatment of mild to moderate depression.  The Cochran calculation revealed that there was not 
significant heterogeneity among included studies and that it would be appropriate to combine 
these studies into one meta-analysis.  The pooled risk ratio for this comparison, calculated using 
a random effects model, was 1.0513 [95% CI: 0.8948 to 1.2352] with a p-value of 0.5428.  These 
results do not demonstrate a statistically significant difference between the SJW and other 
antidepressant groups.  In the studies analyzed, response rates of patients treated with SJW did 
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not differ significantly from response rates of those treated with other antidepressants.  Please 
see figure 3 for the forest plot of the results from this meta-analysis. 
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Figure 3. Forest plot produced through meta-analysis of included studies comparing SJW to 
other antidepressants.  The pooled risk ratio for this comparison, calculated using a random 
effects model, was 1.0513 [95% CI: 0.8948 to 1.2352] with a p-value of 0.5428.  This 
comparison indicates that there is no significant difference in response to treatment with SJW 
versus treatment with other antidepressants.  This demonstrates that SJW is not different from, or 
is equivalent to, the other antidepressants studied in treating mild to moderate depression. 
 
 
SJW versus SSRI 
 A subset of five studies was separately analyzed to compare SJW versus SSRI in the 
treatment of mild to moderate depression.  Since tricyclic antidepressants are not first-line 
treatment for depression, the studies that compared SJW to Imipramine were excluded from this 
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comparison.
20, 40
  The Cochran calculation revealed that there was not significant heterogeneity 
among included studies and that it would be appropriate to combine these studies into one meta-
analysis.  The pooled risk ratio for this comparison, calculated using a random effects model, 
was 1.0066 [95% CI: 0.7694 to 1.317] with a p-value of 0.9615.  These results do not 
demonstrate a statistically significant difference between the SJW and SSRI groups.  In the 
studies analyzed, response rates of patients treated with SJW did not differ significantly from 
response rates of those treated with SSRI’s.  Please see figure 4 for a forest plot of the results 
from this meta-analysis. 
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Figure 4. Forest plot produced through meta-analysis of included studies comparing SJW to 
SSRI.  The pooled risk ratio for this comparison, calculated using a random effects model, was 
1.0066 [95% CI: 0.7694 to 1.317] with a p-value of 0.9615.  This comparison indicates that there 
is no significant difference in response to treatment with SJW versus treatment with an SSRI.  
This demonstrates that SJW is not different from, or is equivalent to, the SSRI’s studied in 
treating mild to moderate depression. 
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Funnel Plots 
 Statistical analysis was used to identify sources of bias that may have affected the results 
of the set of studies on SJW included in this analysis.  The Cochran calculation for homogeneity 
demonstrated the lack of significant heterogeneity between the studies included in the 
comparison of SJW versus placebo.  The same is true for the comparisons of SJW versus other 
antidepressants and SJW versus SSRI.  This initial calculation revealed that it was acceptable to 
combine the studies in each comparison for the purposes of producing a pooled outcome 
measure.  Further analysis compared the treatment effects from each included study to certain 
other characteristics of these studies.  Analyses produced three funnel plots for each comparison.  
Plots compared the natural log of each studies risk ratio to the sample size, p-value, and standard 
error.  The solid line seen on each plot represents the pooled risk ratio for each comparison. 
 
SJW versus Placebo 
 Funnel plots for this comparison revealed two outliers when individual studies risk ratios 
were compared to either sample size or level of significance (p-value).  Schrader appeared to 
over-estimate the effects of SJW,
9
 while the study performed by the HDTSG seemed to 
underestimate SJW effectiveness.
21
  This result is demonstrated graphically by funnel plots 5A 
and 5B.  In these plots, the study by HDTSG is further to the left of the remainder of included 
studies that are clustered around the pooled risk ratio.  Points plotted to the left of the pooled risk 
ratio represent studies that favor the null hypothesis that SJW is not better than placebo.  
Schrader’s study is represented by the point that is well to the right of the pooled risk ratio, in 
favor of a positive effect.  A third funnel plot graphs individual study results versus standard 
 31 
error.  This comparison is designed to emphasize biases inherent in studies of smaller sample 
size.  In this plot, seen in 5C, the studies by HDTSG and Schrader are outliers, with HDTSG 
again favoring lack of significant difference between SJW and placebo and Schrader favoring a 
positive effect for SJW.  Please see figure 5 for funnel plots from this analysis. 
 
5A.       5B. 
 
 
 
 
 
 
 
 
5C.       Figure 5. Funnel plots comparing risk  
       ratio in studies comparing SJW to placebo to 
       (A) sample size, (B) p-value, and (C)  
       standard error. 
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SJW versus Other Antidepressants 
 Funnel plots for this comparison demonstrate clustering of included studies around the 
solid line representing the pooled risk ratio regardless of sample size or p-value.  Figure 6A 
shows that the sample size of an included study does not predict effect size.  Figure 6B 
demonstrates that studies that support the null hypothesis that there is no difference between 
SJW and the other antidepressants studied and studies that reject this null hypothesis are equally 
distributed around the pooled risk ratio.  Figure 6C shows that included studies are evenly 
distributed around the pooled risk ratio regardless of variance of the effect estimate within each 
included study.  Please see figure 6 for funnel plots from this analysis. 
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6A.       6B. 
 
 
 
 
 
 
6C.       Figure 6. Funnel plots comparing risk  
       ratio in studies comparing SJW to other  
       antidepressants to (A) sample size, (B) p- 
       value, and (C) standard error. 
 
 
 
 
 
 
SJW versus SSRI 
 Funnel plots for this comparison demonstrate clustering of included studies around the 
solid line representing the pooled risk ratio regardless of sample size or p-value.  Figure 7A 
shows that the sample size of an included study does not predict effect size.  Figure 7B 
demonstrates that studies that support the null hypothesis that there is no difference between 
SJW and the SSRI’s studied and studies that reject this null hypothesis are equally distributed 
around the pooled risk ratio.  Figure 7C shows that included studies are evenly distributed around 
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the pooled risk ratio regardless of variance of the effect estimate within each included study.  
Please see figure 7 for funnel plots from this analysis. 
 
7A.       7B. 
 
 
 
 
 
 
7C.       Figure 7. Funnel plots comparing risk  
       ratio in studies comparing SJW to other  
       antidepressants to (A) sample size, (B) p- 
     value, and (C) standard error.
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DISCUSSION 
 
 Before studying a novel antidepressant, one must review where pharmacotherapy fits in 
the treatment of depression.  Initiating treatment for depression follows careful diagnosis and 
assessment of the patient for suicidal or self-injurious thoughts or plans.  Use of one of several 
available diagnostic tools can assist clinical acumen in determining severity of depression.  If a 
patient is severely depressed, then monotherapy with any antidepressant is inappropriate.  If 
mildly to moderately depressed, however, it may be appropriate to begin therapy with an 
antidepressant.  Research has demonstrated that monotherapy for depression is not as effective as 
combining pharmacotherapy and psychotherapy.  Therefore, if practicing according to current 
best evidence, a physician would prescribe an antidepressant and refer the depressed patient to 
counseling once he or she had made the diagnosis of mild to moderate depression.  In Germany, 
where several standardized SJW extracts are available and SJW has been approved by the 
appropriate government agency, SJW plays an important role as a cheap and safe part of 
outpatient treatment for depression.
41
  In the US, however, commercially available SJW extracts 
are not standardized and are not currently regulated by the FDA.  Under current conditions, SJW 
should not play a role in treatment for depression. 
 Like many herbal medications, however, SJW has found popularity in the US 
marketplace.  Several sources report that sales of SJW products have increased over the past 
decade.
41-43
  As with other herbal supplements, many patients do not report their use of 
supplements to their physicians unless specifically asked.  As a result, it is difficult to assess the 
potential for important drug interactions.  Since herbal supplements do not go through the same 
FDA approval process as synthetic pharmaceuticals, it is difficult to predict what adverse events 
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are possible with use of SJW.  Over recent years, both adverse events and important drug 
interactions have been coming to light through post-market reports on SJW products in the US.  
Adverse events include serotonin syndrome when SJW is taken at the same time as a monoamine 
oxidase inhibitor or a SSRI 
44
 as well as several effects resulting from activation of the 
cytochrome p450 enzyme complex.  Such p450 effects include lowering of serum cyclosporine 
concentrations leading to graft rejection in transplant patients,
45
 lowering of hormone levels 
leading to breakthrough bleeding in women on oral contraceptives to control menstrual 
bleeding,
46
 and decreased INR in patients taking coumadin 
47
 or lowering serum digoxin 
concentration in cardiac patients.
48
  Each of these examples represents an easily preventable 
adverse event.  Such events are only preventable, however, if the provider is aware of the 
potential of SJW for such interactions and that the patient is taking SJW.  If the FDA treated 
herbal supplements, including SJW, as any other pharmaceutical, it would be possible to more 
closely observe and regulate their use.  More specifically, pre-market research would uncover 
significant potential adverse events and alert physicians so that they may properly counsel 
patients considering taking SJW. 
 This analysis set out to answer whether recent research has shown SJW to be effective in 
treating mild to moderate depression.  Statistical analysis did not identify any significant 
heterogeneity in the studies included in the three comparisons.  While it may have been 
appropriate to combine the studies used for each comparison, the resulting pooled outcomes 
measures must still be critically reviewed.  To begin, the pooled outcomes measures for this 
analysis indicate that SJW is significantly more effective than either placebo and equivalent to 
other antidepressants in treating mild to moderate depression.  Closer analysis reveals that there 
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may be more questions raised by this analysis than answered through the meta-analysis of 
included studies. 
 Studies of SJW have been performed in two countries with decidedly differing views on 
its utility as an antidepressant.  European nations have a more accepting view towards herbal 
remedies, with SJW being prescribed more often than Prozac in Germany.
14
  The medical 
community in the United States, however, is less accepting of herbal medicines.  This attitude is 
reflected in the conclusions of both studies comparing SJW to placebo or other antidepressants 
conducted in the US and published in JAMA.  Shelton and associates found that SJW was not 
more effective than placebo in treatment of mild to moderate depression.
28
  The HDTSG also 
found that SJW was not more effective than placebo and added that SJW was not equivalent to 
Sertraline in treating mild to moderate depression.
21
  These investigators evaluated past studies 
of SJW and determined that past studies lacked the methodological rigor to give credence to past 
conclusions that SJW was effective in treating depression. 
 Shelton, et al and HDTSG took extra steps to ensure meaningful conclusions.  These 
measures included using DSM-IV criteria to define mild to moderate depression at baseline, 
using intention to treat analysis, sufficient study length to detect differences between treatments, 
and using an appropriate dose of any other antidepressant being compared to SJW.  Applying 
DSM-IV criteria to subjects at baseline allows for more accurate clinical diagnosis and inclusion 
of only mild to moderately depressed subjects.  Other studies have used ICD-10 criteria, which 
may mask some improperly diagnosed subjects, including those whose depressed mood may lift 
spontaneously regardless of treatment.  Both of these studies were 8 weeks in length.  A strong 
argument could be made that study length should be longer to allow for real differences to 
 38 
manifest between study groups.  Eight weeks is generally the shortest period considered to be a 
legitimate trial for an antidepressant.  The dose of Sertraline used in the HDTSG study, 50 to 
100-mg, is the average therapeutic dose for this SSRI.
49
  Both of these studies used sufficient 
sample size to detect differences between groups. 
 In comparison to the studies by Shelton, et al and HDTSG, other studies in this analysis 
have not met the proposed standards for methodological rigor.  The most common weaknesses of 
the other studies includes failing to use DSM-IV criteria to define mild to moderate depression, 
duration too short to detect differences, differential loss to follow-up, and insufficient sample 
size.  These other studies also share some other characteristics.  Except for studies by Shelton 
and associates,
28
 HDTSG,
21
 and Brenner, et al,
38
 studies included in this analysis were mostly 
performed in Germany and published in lesser-known journals.  Even Brenner’s study was 
published in a lesser-known journal, whereas the studies by Shelton’s group and the HDTSG 
were published in JAMA, widely considered one of the most respected journals in medicine.  
Due to an assumed more rigorous peer review process, these two studies may reasonably be 
considered to carry more subjective and objective weight when evaluating the literature on this 
subject published since 1998. 
 Only two studies in this analysis employed a design sufficient to control for the placebo 
effect.  The placebo effect confounds studies of antidepressants by making it more likely to 
conclude a novel therapy is more effective than an SSRI (if studied without placebo) or not as 
effective as placebo (if studied alone versus placebo).
50
  Only two studies included in this 
analysis have included both placebo and other antidepressant groups in comparison to SJW.  
Philipp, et al compared SJW to both placebo and Imipramine.  This group concluded that SJW 
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was more effective than placebo and as effective as Imipramine.
20
  This analysis concluded that 
this was a fair study though its conclusions are weakened by its use of a dose of Imipramine well 
below the average therapeutic dose.
49
  Its conclusions are made even less useful since 
Imipramine is no longer first line pharmacotherapy for depression. 
 HDTSG more successfully employs adequate design to reduce the placebo effect.  In fact, 
this study demonstrates the model study design and methodology that will allow future studies to 
accurately assess the effectiveness of SJW.  This model design includes a placebo group to test 
the effectiveness of SJW versus no treatment.  Using such methods as a standard pill size across 
all groups should adequately blind this placebo group.  The study should be from 8 to 12 weeks 
to give an adequate trial of medication and time to adjust dosages if necessary.  Since SSRI is 
currently the first line pharmacotherapy for depression, SJW should be compared to an adequate 
dose of a SSRI.  Standard formulations of both SJW and SSRI should be used.  These 
formulations of SJW should reflect what is currently available in the marketplace.  Future studies 
should also meet the conditions for methodological rigor set forth by the HDTSG.
21
  According 
to this analysis, there is one study that adequately compares SJW to placebo and one study that 
adequately compares SJW to an SSRI.  More work is needed before any final conclusions can be 
drawn about the effectiveness of SJW in treating mild to moderate depression. 
 This review was limited by its restriction to English language journals, to published data 
and to studies published from 1998 to present.  There may be unpublished data either proving or 
disproving the effectiveness of SJW.  Inclusion of foreign language journals may reveal more 
studies appropriate for this review, especially since a majority of studies found were performed 
in Germany.  Studies prior to 1998 were excluded secondary to methodological weakness.  
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Reviewing these studies through a methodologically rigorous eye may identify some studies that 
would help shed light on SJW effectiveness when compared to placebo.  The small number of 
studies included weakened the meta-analysis.  Repeating this review at a future date after more 
studies meeting criteria for methodological rigor have been performed would increase the 
strength of the meta-analysis. 
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